MARKET

NTGN

NTGN

Neon Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.640
+0.190
+7.76%
After Hours: 2.880 +0.24 +9.09% 19:02 03/31 EDT
OPEN
2.500
PREV CLOSE
2.450
HIGH
2.900
LOW
2.300
VOLUME
942.90K
TURNOVER
--
52 WEEK HIGH
7.51
52 WEEK LOW
0.8800
MARKET CAP
25.40M
P/E (TTM)
-0.9220
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NTGN stock price target is 8.58 with a high estimate of 30.00 and a low estimate of 1.500.

EPS

NTGN News

More
  • BioNTech Announces Full Year 2019 Financial Results and Corporate Update
  • GlobeNewswire · 19h ago
  • SHAREHOLDER INVESTIGATION: Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies NTGN, FSB, FSCT, QGEN
  • GlobeNewswire · 03/24 19:11
  • FTSV, MEET, MINI, and NTGN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
  • GlobeNewswire · 03/24 16:28
  • Lifshitz Law Firm, P.C. Announces Investigation of Neon Therapeutics, Inc., Qiagen N.V., Stein Mart, Inc., and Taubman Centers, Inc.
  • GlobeNewswire · 03/23 21:21

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About NTGN

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.
More

Webull offers kinds of Neon Therapeutics Inc stock information, including NASDAQ:NTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTGN stock news, and many more online research tools to help you make informed decisions.